Enlivex Therapeutics Ltd.
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
ENLV | NDAQ
Overview
Corporate Details
- ISIN(s):
- USM201561018
- LEI:
- Country:
- United States of America
- Address:
- 37 DEREH MENACHEM BEGIN ST., 0 TEL AVIV
- Website:
- https://www.enlivex.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company specializing in macrophage reprogramming immunotherapy. The company's lead product candidate is Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore immune system balance. By modulating macrophages, Allocetra™ aims to treat a range of life-threatening and debilitating conditions characterized by immune hyper-responses. Enlivex is currently evaluating the therapy in clinical trials for multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Enlivex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Enlivex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Enlivex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
